Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

. 2020 Dec ; 55 (12) : 2335-2338. [epub] 20200522

Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic

Typ dokumentu dopisy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid32444863
E-zdroje Online Plný text
Odkazy

PubMed 32444863
PubMed Central PMC8497266
DOI 10.1038/s41409-020-0946-x
PII: 10.1038/s41409-020-0946-x
Knihovny.cz E-zdroje

Erratum v

PubMed

Zobrazit více v PubMed

Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–18. doi: 10.1056/NEJMoa1314583.. PubMed DOI PMC

Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica. 2017;102:e156–e159. doi: 10.3324/haematol.2016.151738.. PubMed DOI PMC

Norman JE, Schouten HC, Dreger P, Robinson SP. The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies. Bone Marrow Transpl. 2018. 10.1038/s41409-018-0372-5. PubMed

Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018;124:1733–42. doi: 10.1002/cncr.31264. PubMed DOI PMC

Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203. doi: 10.1182/blood-2016-03-707133.. PubMed DOI PMC

Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, et al. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016;122:2505–11. doi: 10.1002/cncr.30069.. PubMed DOI PMC

Heinzelmann F, Bethge W, Beelen DW, Engelhard M, Kroger N, Dreger P, et al. Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. Bone Marrow Transpl. 2016;51:654–62. doi: 10.1038/bmt.2015.348.. PubMed DOI

Robinson SP, Boumendil A, Finel H, Schouten H, Ehninger G, Maertens, J et al. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control. An analysis from the Lymphoma Working Party of the EBMT. Ann Oncol. 2016. 10.1093/annonc/mdw124. PubMed

Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111:5530–6. doi: 10.1182/blood-2008-01-136242.. PubMed DOI PMC

Pinana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Diez-Martin JL, et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica. 2010;95:1176–82. doi: 10.3324/haematol.2009.017608.. PubMed DOI PMC

Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC) Haematologica. 2007;92:627–34. doi: 10.3324/haematol.10924. PubMed DOI

Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31:1624–30. doi: 10.1200/JCO.2012.47.1862.. PubMed DOI

Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, et al. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 2016;128:2510–6. doi: 10.1182/blood-2016-06-718106.. PubMed DOI PMC

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35:826–33. doi: 10.1200/JCO.2016.70.4320.. PubMed DOI PMC

Abu-Eid R, Samara RN, Ozbun L, Abdalla MY, Berzofsky JA, Friedman KM, et al. Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol Res. 2014;2:1080–9. doi: 10.1158/2326-6066.CIR-14-0095.. PubMed DOI PMC

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace